Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis

被引:33
|
作者
Cheng, Yao-Wen [1 ]
Alhaffar, Dana [1 ]
Saha, Srishti [2 ]
Khanna, Sahil [2 ]
Bohm, Matthew [1 ]
Phelps, Emmalee [1 ]
Ghabril, Marwan [1 ]
Orman, Eric [1 ]
Sashidhar, Sagi [1 ]
Rogers, Nicholas [1 ]
Xu, Huiping [3 ,4 ]
Khoruts, Alexander [5 ]
Vaughn, Byron [5 ]
Kao, Dina [6 ]
Wong, Karen [6 ]
Cammarota, Giovanni [7 ]
Ianiro, Gianluca [7 ]
Dhere, Tanvi [8 ]
Kraft, Colleen S. [9 ,10 ]
Mehta, Nirja [9 ]
Woodworth, Michael H. [9 ]
Allegretti, Jessica R. [11 ]
Nativ, Lotem [11 ]
Marcus, Jenna [11 ]
El-Nachef, Najwa [12 ]
Fischer, Monika [1 ]
机构
[1] Indiana Univ Sch Med, Div Gastroenterol, Indianapolis, IN 46202 USA
[2] Mayo Clin, Dept Gastroenterol & Hepatol, Rochester, MN USA
[3] Indiana Univ, Richard M Fairbanks Sch Publ Hlth, Dept Biostat, Indianapolis, IN 46204 USA
[4] Indiana Univ, Sch Med, Indianapolis, IN USA
[5] Univ Minnesota, Div Gastroenterol Hepatol & Nutr, Minneapolis, MN USA
[6] Univ Alberta, Dept Med, Div Gastroenterol, Edmonton, AB, Canada
[7] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli, Gastroenterol & Oncol Area, Ctr Digest Dis, Rome, Italy
[8] Emory Univ, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA
[9] Emory Univ, Dept Med, Div Infect Dis, Atlanta, GA 30322 USA
[10] Emory Univ, Dept Pathol, Atlanta, GA 30322 USA
[11] Brigham & Womens Hosp, Dept Med, Div Gastroenterol Hepatol & Endoscopy, 75 Francis St, Boston, MA 02115 USA
[12] Univ Calif San Francisco, Dept Med, Div Gastroenterol, San Francisco, CA 94143 USA
基金
美国国家卫生研究院;
关键词
Intestinal Microbiota; Infectious Diarrhea; MELD; Bacterial Infection; PATHOLOGICAL BACTERIAL TRANSLOCATION; LIVER; GUIDELINES; PROBIOTICS; DIAGNOSIS; UPDATE;
D O I
10.1016/j.cgh.2020.06.051
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Clostridioides difficile infection (CDI) harms a large proportion of patients with cirrhosis. Fecal microbiota transplantation (FMT) is recommended for recurrent CDI, but its effects in patients with cirrhosis have not been established. We performed a multicenter observational study to evaluate the efficacy and safety of FMT for CDI in patients with cirrhosis. Methods: We performed a retrospective study of 63 adults with cirrhosis (median model for end-stage liver disease score, 14.5; 24 patients with decompensated cirrhosis) who underwent FMT for CDI from January 2012 through November 2018 at 8 academic centers in the United States, Canada, and Italy. We collected data on patient demographics and characteristics of cirrhosis, CDI, and FMT from medical records and compared differences among patients with different severities of cirrhosis, and FMT successes vs failures at the 8-week follow-up evaluation. We also obtained data on adverse events (AEs) and severe AEs within 12 weeks of FMT. Results:Patients underwent FMT for recurrent CDI (55 of 63; 87.3%), severe CDI (6 of 63; 9.5%), or fulminant CDI (2 of 63; 3.2%) primarily via colonoscopy (59 of 63; 93.7%) as outpatients (47 of 63; 76.8%). FMT success was achieved for 54 patients (85.7%). Among FMT failures, a higher proportion used non-CDI antibiotics at the time of FMT (44.4% vs 5.6%; P < .001), had Child-Pugh scores of B or C (100% vs 37.7%; P < .001), used probiotics (77.8% vs 24.1%; P = .003), had pseudomembranes (22.2% vs 0; P = .018), and underwent FMT as inpatients (45.5% vs 19%; P = .039), compared with FMT successes. In multivariable analysis, use of non-CDI antibiotics at the time of FMT (odds ratio, 17.43; 95% CI, 2.00-152.03; P = .01) and use of probiotics (odds ratio, 11.9; 95% CI, 1.81-78.3; P = .01) were associated with a greater risk of FMT failure. FMT-related AEs occurred in 33.3% of patients (21 of 63)-most were self-limited abdominal cramps or diarrhea. There were only 5 severe AEs that possibly were related to FMT; none involved infection or death. Conclusions: In a retrospective study, we found FMT to be safe and effective for the treatment of CDI in patients with cirrhosis.
引用
收藏
页码:1627 / 1634
页数:8
相关论文
共 50 条
  • [21] Fecal microbiota transplantation for recurrent Clostridioides difficile infection in patients with concurrent ulcerative colitis
    Gholam-Mostafaei, Fahimeh Sadat
    Yadegar, Abbas
    Aghdaei, Hamid Asadzadeh
    Shahrokh, Shabnam
    Daryani, Nasser Ebrahimi
    Zali, Mohammad Reza
    ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA, 2021, 68 (04) : 279 - 285
  • [22] Immunological mechanisms of fecal microbiota transplantation in recurrent Clostridioides difficile infection
    Soveral, Lucas F.
    Korczaguin, Gabriela G.
    Schmidt, Pedro S.
    Nunes, Isabel S.
    Fernandes, Camilo
    Zarate-Blades, Carlos R.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2022, 28 (33) : 4762 - 4772
  • [23] Beneficial effects of fecal microbiota transplantation in recurrent Clostridioides difficile infection
    Yadegar, Abbas
    Pakpoor, Sepideh
    Ibrahim, Fathima F.
    Nabavi-Rad, Ali
    Cook, Laura
    Walter, Jens
    Seekatz, Anna M.
    Wong, Karen
    Monaghan, Tanya M.
    Kao, Dina
    CELL HOST & MICROBE, 2023, 31 (05) : 695 - 711
  • [24] Diarrhea after fecal microbiota transplantation for recurrent Clostridioides difficile infection
    Krensky, Cole
    Poutanen, Susan M.
    Hota, Susy S.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2019, 191 (20) : E559 - E561
  • [25] Current Challenges in Fecal Microbiota Transplantation for Clostridioides difficile Infection in Children
    Nicholson, Maribeth R.
    Hourigan, Suchitra K.
    Conrad, Maire
    Goyal, Alka
    Jensen, Kyle
    Kelsen, Judith
    Kennedy, Melissa
    Weatherly, Madison
    Kahn, Stacy A.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 (09): : 1954 - 1956
  • [26] Updates and Challenges in Fecal Microbiota Transplantation for Clostridioides difficile Infection in Children
    Hourigan, Suchitra K.
    Nicholson, Maribeth R.
    Kahn, Stacy A.
    Kellermayer, Richard
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2021, 73 (04): : 430 - 432
  • [27] Fecal Microbiota Transplant for Clostridioides Difficile Infection Is Safe and Efficacious in an Immunocompromised Cohort
    Kelly Suchman
    Yuying Luo
    Ari Grinspan
    Digestive Diseases and Sciences, 2022, 67 : 4866 - 4873
  • [28] Fecal Microbiota Transplant for Clostridioides Difficile Infection Is Safe and Efficacious in an Immunocompromised Cohort
    Suchman, Kelly
    Luo, Yuying
    Grinspan, Ari
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (10) : 4866 - 4873
  • [29] Fecal microbiota for recurrent Clostridioides difficile infection
    Venkatesan, Priya
    LANCET INFECTIOUS DISEASES, 2025, 25 (04): : e211 - e211
  • [30] Fecal Microbiota Transplantation for Clostridium difficile Infection in Immunocompromised Patients - Safe or Risky?
    Abu-Sbeih, Hamzah
    Ali, Faisal S.
    Hicklen, Rachel
    Wang, Yinghong
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S115 - S117